Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EO4010 + nivolumab
- Development stage
- Discontinued
- Lead developer
- Enterome
- Modality
- Vaccines & Immunotherapeutics, Peptides, Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
EO4010 + nivolumab is an investigational combination immunotherapy regimen being evaluated for the treatment of microsatellite stable (MSS) and mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC). EO4010 is an off-the-shelf therapeutic cancer vaccine developed by Enterome, consisting of five synthetic microbial-derived peptides (EO2317, EO2318, OMP10, OMP11, and OMP12) that mimic HLA-A2 restricted CD8+ T-cell epitopes of five tumor-associated antigens (TAAs) upregulated in colorectal cancer: BIRC5 (survivin), FOXM1, UBE2C, CDC20, and KIF2C. It also includes the helper peptide Universal Cancer Peptide 2 (UCP2) to stimulate CD4+ T cells. Nivolumab (Opdivo) is a programmed death-1 (PD-1) blocking monoclonal antibody developed by Bristol Myers Squibb. By combining EO4010's ability to expand tumor-specific CD8+ T cells with nivolumab's checkpoint inhibition, the regimen aims to overcome immune tolerance and enhance anti-tumor activity in immunologically cold MSS colorectal tumors.
- Other names
- EO4010 and nivolumabEO-4010 and nivolumabEO 4010 and nivolumabEO4010 plus nivolumabEO-4010 plus nivolumabEO 4010 plus nivolumab
02
Targets
BIRC5 (Survivin)CDC20 (Cell division cycle protein 20 homolog)FOXM1 (Forkhead box protein M1)HLA-A (HLA class I histocompatibility antigen A alpha chain)KIF2C (Kinesin family member 2C)CD274 (Programmed cell death protein 1 ligand 1)PDCD1LG2 (Programmed cell death 1 ligand 2)PDCD1 (Programmed cell death protein 1 receptor)UBE2C (Ubiquitin-conjugating enzyme E2 C)
Beyond the preview
Go deeper on EO4010 + nivolumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EO4010 + nivolumab.